EC
OCS icon

Elequin Capital’s Oculis Holding OCS Stock Holding History

Elequin Capital’s Portfolio OCS Stock Details OCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-300
Closed -$3.3K – 456
2023
Q3 		$3.3K Hold
300
– – ﹤0.01% 303
2023
Q2 		$3.7K Hold
300
– – ﹤0.01% 401
2023
Q1 		$2.23K Buy
+300
New +$2.51K ﹤0.01% 254

Other funds holding OCS

PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SC
Searle & Co Greenwich, Connecticut $445M AUM 41.72% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Elequin Capital's OCS Position: Q4 2023 in Review

Elequin Capital sold out of Oculis Holding (OCS) in Q4 2023, closing a stake of 300 shares — an estimated $3.3K sold.

Elequin Capital first reported a position in OCS in Q1 2023 and held it in 3 quarters. The position peaked at $3.7K in Q2 2023. 7 funds tracked by Wall St. Rank hold OCS as of Q4 2023.

  • Elequin Capital reported no remaining Oculis Holding position as of Q4 2023 after selling out during the quarter.
  • Elequin Capital sold 300 Oculis Holding shares in Q4 2023, an estimated $3.3K.
  • Elequin Capital first reported a position in Oculis Holding in Q1 2023 and held it in 3 quarters.
  • Elequin Capital's Oculis Holding position peaked at $3.7K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Oculis Holding as of Q4 2023.

Based on Elequin Capital's 13F filing for Q4 2023, filed 14 Feb 2024.